An Open-label, Single Dose, Parallel Design, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Oral Dosage Form of LCB01-0371 in Healthy Volunteers
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- LigaChem Biosciences, Inc.
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Pharmacokinetics: Peak Plasma Concentration (Cmax)
Study Overview
Brief Summary
To investigate pharmacokinetics, safety and tolerability of LCB01-0371, LCB01-0371-B after a single oral dose in healthy male subjects.
To investigate safety, tolerability of LCB01-0371 after a single oral dose in healthy male subjects.
Detailed Description
An Open-label, Single dose, Parallel design, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Oral dosage form of LCB01-0371 in Healthy Male Volunteers
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to 40 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy male between 20 and 40 years of age at the time of screening
- •Agree to continue to use a medically reliable dual contraception and not to donate sperm in this protocol for the duration of the study and for 28 days after last dose of investigational product
- •Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements
Exclusion Criteria
- •History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer) within 6 months possibly affecting absorption of clinical trial drugs, or history of surgery (except simple appendectomy and herniotomy)
- •History of hypersensitivity reaction or history of clinically significant hypersensitivity reaction to LCB01-0371 or same class of the study drugs (linezolid) or other drugs including aspirin and antibiotics
- •History of clinically significant disease such as allergic or anaphylactic reaction to drug, cardiovascular, peripheral vascular system, skin, mucous membrane, eye, otorhinolaryngologic system, respiratory, musculoskeletal, infection disease, Gastrointestinal system , liver, biliary system, endocrine, kidney, urogenital system, nervous system, psychiatric system, blood dyscrasia, tumor, fracture, problem(s)
- •blood donation and transfusion within 60 days prior to screening visit
- •Treatment with an other investigational product or Participation in other bioequivalence test within 90 days prior to screening visit
- •Use medication which expected to influence in this study within 30 days prior to screening visit
- •smokers over 10 cigarettes per day within 30 days prior to screening visit or unable to stop smoking in this protocol for the duration of the study from first dose of investigational product
- •drinkers over 3 glasses alcohol drink per week within 30 days prior to screening visit or unable to stop drinking in this protocol for the duration of the study from first dose of investigational product
- •positive result at urine drug screening test or urine nicotine test at screening visit
- •positive result at serum test(hepatitis B, hepatitis C, HIV, syphilis) at screening visit
- •corrected QT interval >450 msec or significant abnormalities on screening ECG
- •other: Patients considered unable perform for the study by the investigator concerning
Arms & Interventions
Group 1: LCB01-0371
Period 1: LCB01-0371 Tablet 400 mg Period 2: LCB01-0371 Tablet 400 mg
Intervention: Group 1:LCB01-0371 (Drug)
Group 1: LCB01-0371
Period 1: LCB01-0371 Tablet 400 mg Period 2: LCB01-0371 Tablet 400 mg
Intervention: Group 2:LCB01-0371 (Drug)
Group 2: LCB01-0371
Period 1: LCB01-0371 Tablet 800 mg Period 2: LCB01-0371 Tablet 1200 mg
Intervention: Group 1:LCB01-0371 (Drug)
Group 2: LCB01-0371
Period 1: LCB01-0371 Tablet 800 mg Period 2: LCB01-0371 Tablet 1200 mg
Intervention: Group 2:LCB01-0371 (Drug)
Outcomes
Primary Outcomes
Pharmacokinetics: Peak Plasma Concentration (Cmax)
Time Frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours
Pharmacokinetics: time to maximum concentration (Tmax)
Time Frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours
Pharmacokinetics: Area under the plasma concentration versus time curve (AUC)
Time Frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours
Secondary Outcomes
- Number of Adverse Event(participants will be followed after hospital stay, an expected average of 16 weeks)